Fig 1: Pan-cancer landscape of STC2 expression, immune associations, and prognostic value. (A) Differential STC2 mRNA expression between normal and tumor tissues across cancer types. Blue and red indicate normal and tumor tissues, respectively. (B) Paired comparison of STC2 expression between normal and tumor tissues. Blue and red indicate normal and tumor tissues, respectively, and lines connect paired samples. (C) Representative Human Protein Atlas immunohistochemical images showing STC2 protein expression in normal and tumor tissues across cancer types. Black boxes indicate regions shown at higher magnification, with dashed lines connecting the corresponding regions. Black scale bars indicate the image scale. (D) Correlations of STC2 expression with stromal score, immune score, and ESTIMATE score across cancer types. (E and F) Correlations between STC2 expression and immune cell infiltration across cancer types. Red and blue indicate positive and negative correlations, respectively, and color intensity represents correlation strength. (G) Forest plots showing the prognostic associations of STC2 with disease specific survival, overall survival, and progression free interval. Points represent hazard ratios and horizontal lines represent 95% confidence intervals. Scale bars, 200 μm and 50 μm.
Fig 2: Identification of an STC2+ endothelial subpopulation with hypoxia and angiogenesis activation in HNSCC. (A) UMAP visualization of STC2 low and STC2 high endothelial cells in normal and tumor tissues. The lower and upper quartiles of STC2 expression were defined as STC2- and STC2+ endothelial cells, respectively. (B) Relative proportions of STC2- and STC2+ endothelial cells in normal and tumor tissues. (C) Comparison of hypoxia scores between STC2- and STC2+ endothelial cells. (D) GO and KEGG enrichment analyses of highly expressed genes in STC2+ endothelial cells. (E) scMetabolism analysis of metabolic pathway activity in STC2- and STC2+ endothelial cells. Circle size represents the relative enrichment level, and color indicates the pathway activity score. (F) Multiplex immunofluorescence staining of HIF1A, STC2, and DAPI in normal and tumor tissues with fluorescence quantification. Scale bars are indicated in the images. (G and H) CellChat analysis showing the number and strength of interactions between STC2- and STC2+ endothelial cells. Red and blue lines indicate interactions originating from STC2+ and STC2- endothelial cells, respectively. (I) Bubble plot showing ligand receptor interactions between endothelial subpopulations. Circle size indicates statistical significance, and color represents communication probability. (J) ANGPT signaling analysis showing communication patterns, pathway interaction strength, and expression of ANGPT2, TEK, ITGA5, and ITGB1. Red and blue denote STC2+ and STC2- endothelial cells, respectively. (K) Top 20 genes with the largest log fold changes following in silico STC2 knockout in tumor endothelial cells. (L) RT qPCR validation of STC2 knockdown efficiency in HUVECs. (M) CCK8 assay evaluating HUVEC viability following STC2 knockdown. (N) Immunofluorescence staining of CD31, cytoskeleton, and DAPI in control and STC2 knockdown HUVECs. Scale bars are indicated in the images. (O) RT qPCR analysis of VEGF, CD31, vWF, and eNOS expression following STC2 knockdown. (P) Scratch wound assay evaluating HUVEC migration at 0 and 24 h following STC2 knockdown. CD31, STC2, and nuclei are shown in green, red, and blue, respectively. **P < 0.01 and ***P < 0.001. Scale bars, 200 μm.
Fig 3: Functional characteristics and tumor microenvironment relevance of STC2 in HNSCC. (A) GO enrichment analysis of genes positively and negatively correlated with STC2. Colors distinguish positively and negatively correlated gene sets. (B) KEGG enrichment analysis of STC2 related genes. Colors distinguish positively and negatively correlated pathways. (C) GSEA showing enrichment of malignant pathways associated with STC2 expression. Ridge colors indicate adjusted P values. (D) Correlation analysis of STC2, the Hypoxia Score, and tumor related pathways. Edge color and width indicate Mantel P values and correlation coefficients, respectively, while tile color represents Pearson correlation coefficients among pathways. (E) UMAP plots showing major cell populations in normal and tumor tissues. Colors indicate annotated cell types, and the colored header bars distinguish normal and tumor samples. (F) UMAP feature plots showing STC2 expression across cells in normal and tumor tissues. Color intensity indicates STC2 expression. (G) Dot plot showing STC2 expression across major cell types. Dot size represents the percentage of STC2 expressing cells, and color intensity indicates expression level. (H and I) Correlation between STC2 expression and endothelial cell infiltration in GSE65858 and TCGA HNSC, respectively. Blue dots represent individual samples, yellow lines indicate fitted regression lines, and gray shaded areas represent 95% confidence intervals. (J) Spatial transcriptomic maps showing the distributions of endothelial cells, PECAM1, and STC2. Color scales indicate relative signal intensity. (K) Representative MIF images and quantitative analysis of CD31 and STC2 in normal and tumor tissues. CD31, STC2, and nuclei are shown in green, red, and blue, respectively. *P < 0.05 and **P < 0.01. Scale bars, 200 μm.
Fig 4: Identification and validation of STC2 as a key hypoxia-driven regulator in HNSCC. (A) Intersection of candidate genes identified by eight machine learning algorithms, showing STC1, STC2, and RORA as shared genes, with representative feature importance rankings from KNN and random forest models. (B–D) RT qPCR validation of RORA, STC1, and STC2 expression in normal and tumor tissues. (E) Validation of STC2 overexpression in the E MTAB 8588, GSE42743, GSE75538, and TCGA HNSC cohorts. (F) Paired analysis of STC2 mRNA expression between normal and tumor tissues. Lines connect paired samples. (G) Association of STC2 expression with histological grade, clinical stage, and T stage across independent cohorts. (H) Kaplan Meier analysis of overall survival according to STC2 expression. Blue and red curves indicate STC2 low and STC2 high groups, respectively. (I) Representative Human Protein Atlas immunohistochemical images of STC2 expression in normal and tumor tissues. (J) Representative immunohistochemical staining and quantification of STC2 positive area in HNSCC and adjacent normal tissues. *P<0.05, **P<0.01, ***P<0.001. Scale bars, 200 μm.
Fig 5: Hypoxia-related remodeling of intercellular communication networks in HNSCC. (A and B) Correlation heatmaps showing the associations between STC2 expression and different immune cell subsets. Color intensity represents the direction and magnitude of the correlation, and asterisks indicate statistical significance. (C) Violin plots showing canonical marker genes used for cell type annotation. Colors indicate the annotated cell populations. (D) UMAP visualization of the major cell populations identified in HNSCC. Colors indicate different cell types. (E) UMAP visualization comparing the distribution of cell populations between normal and tumor tissues. Colors indicate different cell types. (F) Relative proportions of cell populations in normal and tumor tissues. (G) CellChat analysis showing the number and strength of intercellular interactions among STC2− endothelial cells, STC2+ endothelial cells, and immune cell populations in normal tissues. Node size represents the relative cell population size, and line width represents interaction number or communication strength. Colors indicate the corresponding cell populations. (H) Bubble plot showing ligand receptor interactions among STC2− endothelial cells, STC2+ endothelial cells, and immune cell populations in normal tissues. Dot size indicates statistical significance, and color represents communication probability. (I and J) GALECTIN and ANGPTL signaling networks in normal tissues, respectively. Heatmaps, violin plots, and chord diagrams illustrate signaling activity, expression patterns of signaling related genes, and intercellular communication patterns. (K) CellChat analysis showing the number and strength of intercellular interactions among STC2− endothelial cells, STC2+ endothelial cells, and immune cell populations in tumor tissues. Node size represents the relative cell population size, and line width represents interaction number or communication strength. Colors indicate the corresponding cell populations. (L) Bubble plot showing ligand receptor interactions among STC2− endothelial cells, STC2+ endothelial cells, and immune cell populations in tumor tissues. Dot size indicates statistical significance, and color represents communication probability. (M and N) GALECTIN and ANGPTL signaling networks in tumor tissues, respectively. Heatmaps, violin plots, and chord diagrams illustrate signaling activity, expression patterns of signaling related genes, and intercellular communication patterns. (O) Spatial CellChat analysis showing the number and strength of intercellular interactions among epithelial cells, T cells, monocytes, fibroblasts, plasma cells, and STC2+ endothelial cells in tumor tissues. Node size represents the relative abundance of each cell population, and line width represents interaction number or communication strength. Colors indicate the corresponding cell populations. (P) Spatial characterization of the GALECTIN signaling network in tumor tissues. Spatial maps, heatmaps, violin plots, and chord diagrams illustrate the spatial distribution of signaling activity, communication probabilities, expression patterns of signaling related genes, and major ligand receptor interactions, including LGALS9 with CD44 and CD45. (Q) Spatial characterization of the ANGPTL signaling network in tumor tissues. Spatial maps, heatmaps, violin plots, and chord diagrams illustrate the spatial distribution of signaling activity, communication probabilities, expression patterns of signaling related genes, and major ligand receptor interactions, including ANGPTL2 with the ITGA5 and ITGB1 receptor complex.
Supplier Page from OriGene Technologies for Stanniocalcin 2 (STC2) Human shRNA Plasmid Kit (Locus ID 8614)